LC
CGON icon

Lindbrook Capital’s CG Oncology CGON Stock Holding History

Lindbrook Capital’s Portfolio CGON Stock Details CGON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$1.18K Buy
+48
New +$1.35K ﹤0.01% 2418

Other funds holding CGON

DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return

Lindbrook Capital's CGON Position: Q1 2025 in Review

Lindbrook Capital opened a new position in CG Oncology (CGON) in Q1 2025: 48 shares worth $1.18K. The stake represents ﹤0.01% of the portfolio and ranks #2418 among its holdings.

142 funds tracked by Wall St. Rank hold CGON as of Q1 2025.

  • Lindbrook Capital held 48 shares of CG Oncology worth $1.18K as of Q1 2025.
  • CG Oncology was a new Lindbrook Capital position in Q1 2025.
  • CG Oncology made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #2418 holding.
  • 142 funds tracked by Wall St. Rank held CG Oncology as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.